T cell receptor-therapy in HBV-related hepatocellularcarcinoma

Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2015-06, Vol.4 (6), p.e1008354-e1008354
Main Authors: Bertoletti, Antonio, Brunetto, Maurizia, Maini, Mala K, Bonino, Ferruccio, Qasim, Waseem, Stauss, Hans
Format: Article
Language:English
Subjects:
Author's View
CHB, Chronic hepatitis B
HBV
hepatocellularcarcinoma
SCID, Severe combined immunodeficiency
T cell therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.1080/2162402X.2015.1008354